NCT02141438 - Observational Study for the Evaluation of Long-term Safety of Radium-223 Used for the Treatment of Metastatic Castration Resistant Prostate Cancer | Biotech Hunter

Enrollment

1,472

Participants

Timeline

Start Date

August 20, 2014

Primary Completion Date

August 2, 2024

Study Completion Date

October 24, 2024

Conditions

Metastatic Castration-resistant Prostate Cancer

Interventions

DRUG

Radium-223 dichloride (Xofigo, BAY88-8223)

This is a non-interventional study, the drug is used in its authorized indication from commercial supply. The decision to treat with Radium-223 will be agreed upon between the physician and the patient independently and prior to providing the patient study information. Treatment with Radium-223 should follow the approved local product information.

Trial Locations (68)

Unknown

Anchorage

Scottsdale

Daly City

Long Beach

Sacramento

San Diego

Colorado Springs

Boca Raton

Fort Myers

Jacksonville

Lakewood Rch

Plantation

Atlanta

Decatur

Honolulu

Evanston

Warrenville

Wichita

Ashland

New Orleans

Baltimore

Rockville

Towson

Boston

Troy

St Louis

Billings

Omaha

Lebanon

Neptune City

Township

Buffalo

East Setauket

Lake Success

Winston-Salem

Middleburg Heights

Oklahoma City

Springfield

Abington

Charleston

Myrtle Beach

Nashville

Houston

Lubbock

San Antonio

Temple

Charlottesville

Virginia Beach

Seattle

Multiple Locations